文献速递其他结缔组织病类风湿关节炎

TNF抑制剂影响mRNA疫苗接种后刺突特异性B细胞应答的诱导与维持

TNF inhibitors affect the induction and maintenance of spike-specific B-cell responses after mRNA vaccination.
PubMed 文献 · RMD Open · 2025-08-04

研究比较15例接受TNF抑制剂治疗的炎症性肠病患者与9例未接受系统性免疫抑制的炎症性肠病患者及10例健康对照,发现TNF抑制剂不影响刺突特异性CD4+ T细胞频率与表型,但降低总刺突特异性B细胞频率及接种后3-6个月IgG+记忆B细胞频率,并在第二剂接种后第7天即减少生发中心来源的CD11c- CD71+活化B细胞诱导,而不影响CD11c+ B细胞。

要点

  • TNF抑制剂不影响刺突特异性CD4+ T细胞频率及表型(含滤泡辅助性T细胞)。
  • TNF抑制剂治疗者总刺突特异性B细胞频率降低,接种后3-6个月IgG+记忆B细胞频率更低。
  • 第二剂接种后第7天,TNF抑制剂减少生发中心来源的CD11c- CD71+活化B细胞诱导,不影响CD11c+ B细胞。

核心结论

  • 数据提示TNF抑制剂治疗影响生发中心来源B细胞的分化,这可能解释其对体液免疫应答的影响。

研究设计与样本

  • 采用光谱流式细胞术表征SARS-CoV-2刺突特异性B细胞应答,采用活化诱导标志物法检测刺突特异性CD4+ T细胞。
  • 比较15例接受TNF抑制剂治疗的炎症性肠病患者、9例未接受系统性免疫抑制的炎症性肠病患者与10例健康对照。

主要发现

  • 刺突特异性CD4+ T细胞频率与表型(包括滤泡辅助性T细胞)未受TNF抑制剂影响。
  • TNF抑制剂治疗患者总刺突特异性B细胞频率降低。
  • 深度表型分析显示TNF抑制剂治疗患者接种后3-6个月IgG+记忆B细胞频率更低,该数据在TNF抑制剂治疗的类风湿关节炎患者中得到证实。
  • 第二剂接种后第7天,TNF抑制剂治疗已减少生发中心来源的CD11c- CD71+活化B细胞诱导。
  • 与滤泡外B细胞应答相关的CD11c+ B细胞未受TNF抑制剂治疗影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tumour necrosis factor inhibitors (TNFi) are widely used and effective as treatment for immune-mediated inflammatory diseases (IMIDs). However, TNFi therapy causes a faster waning of antibody responses following vaccination. The underlying cause by which TNFi affect humoral immunity remains to be elucidated. The formation of long-lasting, high-affinity antibodies after vaccination results from germinal centre (GC)-derived, T cell-dependent B-cell responses. Therefore, this study investigated how TNFi affect the formation and maintenance of antigen-specific B- and CD4+ T-cell responses following SARS-CoV-2 mRNA vaccination. METHODS: SARS-CoV-2 spike-specific B-cell responses were characterised using spectral flow cytometry. Spike-specific CD4+ T cells were measured using an activation-induced marker assay. 15 patients with inflammatory bowel disease (IBD) treated with TNFi were compared with 9 IBD patients without systemic immunosuppression and 10 healthy controls. RESULTS: Spike-specific CD4+T-cell frequency and phenotype, including T follicular helper cells, were not affected by TNFi. Total spike-specific B-cell frequencies were reduced in TNFi-treated patients. Deep phenotyping revealed lower IgG+memory B-cell frequencies in TNFi-treated patients 3-6 months after vaccination. These data were confirmed in TNFi-treated rheumatoid arthritis patients. Interestingly, already at day 7 after the second vaccination, TNFi therapy reduced the induction of class-switched CD11c- CD71+activated B cells, which are believed to be GC-derived. Conversely, CD11c+B cells, associated with extrafollicular B-cell responses, were not affected by TNFi therapy. CONCLUSIONS: These data suggest that TNFi therapy affects the differentiation of GC-derived B cells, which may explain its effect on humoral immune responses.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kummer LY, Kuijper LH, Fernández Blanco L, et al. TNF inhibitors affect the induction and maintenance of spike-specific B-cell responses after mRNA vaccination. RMD Open. 2025. PMID: 40759563. doi:10.1136/rmdopen-2025-005724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。